Loading...
HIV-associated neurocognitive disorders (HAND) range from mild (neuropsychologically impaired) to moderate (minor cognitive motor disorder) to severe (HIV-associated dementia). HAND is now the most common preventable and treatable neurocognitive illness in people younger than 50. Direct or indirect oxidative damage is presumed to be the underlying basis. However, biomarkers for HAND remain elusive. Now, two research groups have tested the value of different biomarkers in treating or evaluating patients with HAND.
Schifitto and colleagues conducted a follow-up investigation of transdermal selegiline as an adjuvant antioxidant in HAND. Selegiline decreases oxygen free radicals and increases superoxide dismutase and catalase levels; levels of o…